*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Zhongzhi Pharmaceutical Holdings Limited
# 中智藥業控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3737)**

## CHANGE OF DIRECTOR

This announcement is made pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The board of directors (the "**Board**") of Zhongzhi Pharmaceutical Holdings Limited (the "**Company**") hereby announces that with effect from 6 November 2026:

(i) Mr. Kan Siu Lun, M.H. has been appointed as an independent non-executive director, and the member of each of the audit committee, remuneration committee and the nomination committee of the Company.

(ii) Mr. Zhou Dai Han has resigned as an independent non-executive director, and the member of each of the audit committee, remuneration committee and the nomination committee of the Company.

### APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The biographical details of Mr. Kan Siu Lun, M.H. are set out below:

Mr. Kan Siu Lun M.H. ("**Mr. Kan**"), aged 71, is a seasoned interdisciplinary professional and corporate governance practitioner with extensive experience in public administration, urban planning, heritage conservation, higher education, and community service.

He has held numerous appointments on statutory and public bodies in Hong Kong, including the Town Planning Board, Urban Renewal Authority, Antiquities Advisory Board, The Board of Management of The Chinese Permanent Cemeteries, and the Board of Trustees of the Hong Kong Jockey Club Music and Dance Fund. He has also served as chairman and member of various audit, finance, governance, and advisory committees.

In the professional arena, Mr. Kan served on the Disciplinary Committee and the Investigation Committee of the Hong Kong Institute of Certified Public Accountants, contributing significantly to professional regulation and standards. In higher education, he has maintained a long-standing association with Hong Kong Baptist University, having served on its Court and School of Business Advisory Committee, and currently serves as a Senior Member of the Hong Kong Baptist University Foundation.

In recognition of his distinguished contributions to public service and professional development, Mr. Kan was awarded the Medal of Honour (M.H.) by the Government of the Hong Kong Special Administrative Region.

Mr. Kan has been serving as an independent director of Amber International Holding Limited (Nasdaq: AMBR) since March 2025. Previously, he served as an independent director of iClick Interactive Asia Group Limited from January 2021 to March 2025.

Mr. Kan has entered into a service agreement with the Company for a term of three years commencing on 6 November 2026 until terminated by either party by giving to the other party not less than three months' notice in writing at any time after such initial fixed term.

Pursuant to the service agreement, Mr. Kan is entitled to HK$180,000 per annum (excluding payment pursuant to any discretionary benefits or bonus, granting of share options, or other fringe benefits) for his appointment as an independent non-executive Director.

Save as disclosed above, (i) Mr. Kan has not held any directorships in the past three years in any listed companies in Hong Kong or overseas; (ii) Mr. Kan has not held any other positions in the Company or any of its subsidiaries; (iii) Mr. Kan does not have any relationship with any other directors, chief executives, senior management, substantial, controlling or management shareholders of the Company or any of its subsidiaries or any of their respective associates; (iv) Mr. Kan does not have any interests in the Shares within the meaning of Part XV of SFO; and (v) there is no information relating to Mr. Kan that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules or any other matter concerning Mr. Kan that needs to be brought to the attention of the Shareholders.

Mr. Kan Siu Lun, M.H. has confirmed that (i) he satisfies the independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interests in the business of the Company or its subsidiaries, nor is he connected with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence at the time of his appointment.

## RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces Mr. Zhou Dai Han has resigned with effect from 6 November 2026 due to his other business commitments. Mr. Zhou Dai Han has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange. The Company would like to express gratitude to Mr. Zhou Dai Han for his continuous support and contributions to the Company.

By order of the Board
**Zhongzhi Pharmaceutical Holdings Limited**
**Mr. Lai Zhi Tian**
*Chairman*

Hong Kong, 6 November 2026

*As at the date of this announcement, the Board comprises eight directors. The executive directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Lai Ying Sheng and Mr. Cao Xiao Jun. The non-executive director is Ms. Jiang Li Xia. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Zhu Shang Heng and Mr. Kan Siu Lun.*